Menu
Create an Account
Log in
Home
Activities
Courses and Conferences
HIV In-Person and Virtual Courses
Earn CME From On-Demand Webcasts
The 2022 Ryan White HIV/AIDS Program CLINICAL CONFERENCE
Conference on Retroviruses and Opportunistic Infections
About IAS–USA Courses
Webinars
Upcoming Webinars
2022 On-Demand Webinars
Earn CME From On-Demand Webinars
About Webinars
COVID-19 Dialogue Series
Upcoming Dialogues
On-Demand Dialogues
Topics in Antiviral Medicine
Current Issues
Previous Issues
TAM
Policies and Practices
Resources
Guidelines
HIV Drug Resistance Mutations
Podcasts
On-Demand Webcasts
Slides
Research Collaboration
Useful Resources for COVID-19 Information and Guidance
Practice Question of the Week
Fellow/Student Resources
Other Resources
About
Mission
IAS–USA Scientific Leadership Board
IAS–USA Governance
Core Faculty
Staff
CME
Funding Information
Careers
Donate
Website Policies
FAQs
Contact
H. Nina Kim, MD, MS
H. Nina Kim, MD, MS
University of Washington
University of Washington
Seattle, Washington
Home
Activities
Courses and Conferences
HIV In-Person and Virtual Courses
Earn CME From On-Demand Webcasts
The 2022 Ryan White HIV/AIDS Program CLINICAL CONFERENCE
Conference on Retroviruses and Opportunistic Infections
About IAS–USA Courses
Webinars
Upcoming Webinars
2022 On-Demand Webinars
Earn CME From On-Demand Webinars
About Webinars
COVID-19 Dialogue Series
Upcoming Dialogues
On-Demand Dialogues
Topics in Antiviral Medicine
Current Issues
Previous Issues
TAM
Policies and Practices
Resources
Guidelines
HIV Drug Resistance Mutations
Podcasts
On-Demand Webcasts
Slides
Research Collaboration
Useful Resources for COVID-19 Information and Guidance
Practice Question of the Week
Fellow/Student Resources
Other Resources
About
Mission
IAS–USA Scientific Leadership Board
IAS–USA Governance
Core Faculty
Staff
CME
Funding Information
Careers
Donate
Website Policies
FAQs
Contact
Practice Question of the Week
October 3, 2022: Doxycycline Postexposure Prophylaxis for Bacterial Sexually Transmitted Infections (STIs)
Your patient has been treated 3 times for bacterial STIs over the past 2 years. He is currently on cabotegravir every 2 months for PrEP. Which strategy appears to reduce his subsequent risk of contracting another bacterial STI?
A. Switching PrEP to oral TAF/FTC or TDF/FTC
B. Cefixime 400 mg, taken once after sex
C. Doxycycline 200 mg, taken once after sex
D. Monthly benzathine penicillin, 2.4 million units given intramuscularly
Watch On-demand Webinar
View Related Resources
Leave Feedback
Subscribe
CLOSE
